POERIO, ANGELA
POERIO, ANGELA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
POERIO A.; A. Poerio
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
2011 Soverini, Simona; Vitale, A; Poerio, Angela; Gnani, A; Colarossi, Sabrina; Iacobucci, Ilaria; Cimino, G; Elia, L; Lonetti, Annalisa; Vignetti, M; Paolini, Stefania; Meloni, G; di Maio, V; Papayannidis, Cristina; Amabile, M; Guarini, A; Baccarani, Michele; Martinelli, Giovanni; Foa', R.
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience
2009 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Abbenante, Mariachiara; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Piccaluga, PIER PAOLO; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia
2009 Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti, Gianantonio; Palandri, Francesca; Castagnetti, Fausto; Breccia, M; Levato, L; Gugliotta, Gabriele; Capucci, A; Cedrone, M; Fava, C; Intermesoli, T; Cambrin, Gr; Stagno, F; Tiribelli, M; Amabile, Marilina; Luatti, Simona; Poerio, Angela; Soverini, Simona; Testoni, Nicoletta; Martinelli, Giovanni; Alimena, G; Pane, F; Saglio, G; Baccarani, Michele; GIMEMA CML Working, Party
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri, Francesca; Castagnetti, Fausto; Soverini, Simona; Poerio, Angela; Gugliotta, Gabriele; Luatti, Simona; Amabile, Marilina; Martinelli, Giovanni; Rosti, Gianantonio; Baccarani, Michele
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
2009 Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
2008 Palandri, Francesca; Iacobucci, Ilaria; Martinelli, Giovanni; Amabile, Marilina; Poerio, Angela; Testoni, Nicoletta; Soverini, Simona; Castagnetti, Fausto; DE VIVO, Antonio; Breccia, M; Specchia, G; Abruzzese, E; Martino, B; Cilloni, D; Saglio, G; Pane, F; Liberati, Am; Rosti, Gianantonio; Baccarani, Michele; GIMEMA Working Party on, C. M. L.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
2006 IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia
2006 Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib
2004 SOVERINI S; MARTINELLI G.; AMABILE M; POERIO A; BIANCHINI M; ROSTI G; PANE F; SAGLIO G; BACCARANI M.
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
2004 BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S.; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA